文献速递垂体与肾上腺疾病

长效帕瑞肽每月一次治疗库欣病的疗效与安全性:一项12个月临床试验

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-10-12

这项3期试验将150例库欣病患者随机分配至长效帕瑞肽10 mg或30 mg每4周肌内注射治疗12个月。第7个月时,10 mg组41.9%、30 mg组40.8%的患者尿游离皮质醇均值降至正常上限或以下。最常见不良事件为高血糖、腹泻、胆石症、糖尿病和恶心,两例死亡判定与药物无关。

要点

  • 长效帕瑞肽10 mg组第7个月尿游离皮质醇均值正常化比例为41.9%,30 mg组为40.8%
  • 常见不良事件包括高血糖(10 mg组49%,30 mg组47%)、腹泻、胆石症、糖尿病和恶心
  • 研究者认为长效帕瑞肽是部分库欣病患者的有效治疗选择,每月给药方便

核心结论

  • 长效帕瑞肽使约40%的库欣病患者在第7个月时尿游离皮质醇均值恢复正常,安全性特征与每日两次皮下注射帕瑞肽相似。
  • 研究者认为长效帕瑞肽是部分经初始手术后持续或复发疾病、或不适合手术的库欣病患者的有效治疗选择,并提供方便的每月给药方案。

研究设计与样本

  • 3期临床试验,从19个国家57个中心招募18岁及以上、持续或复发或新发(非手术候选)库欣病患者。
  • 纳入标准包括尿游离皮质醇均值(三次24小时样本)为正常上限的1.5-5.0倍、晨血浆促肾上腺皮质激素正常或高于正常、库欣综合征源于垂体。
  • 排除既往帕瑞肽治疗、6个月内米托坦治疗、10年内垂体放疗者。
  • 采用交互响应技术系统按1:1随机分配(区组大小4)至肌内注射帕瑞肽10 mg或30 mg每4周一次治疗12个月(核心期),按筛选时尿游离皮质醇均值分层(1.5至<2.0倍正常上限和2.0-5.0倍正常上限)。
  • 主要终点为第7个月时每组尿游离皮质醇均值≤正常上限的患者比例,疗效分析基于意向治疗;试验注册号NCT01374906。

主要发现

  • 2011年12月28日至2014年12月9日期间随机分配150例患者至帕瑞肽10 mg组(74例,49%)或30 mg组(76例,51%)。
  • 达到主要疗效终点的患者比例:10 mg组74例中31例(41.9%[95%CI 30.5-53.9]),30 mg组76例中31例(40.8%[29.7-52.7])。
  • 最常见不良事件:高血糖10 mg组36例(49%)vs 30 mg组36例(47%),腹泻26例(35%)vs 33例(43%),胆石症15例(20%)vs 34例(45%),糖尿病14例(19%)vs 18例(24%),恶心15例(20%)vs 16例(21%)。
  • 怀疑与研究药物相关的严重不良事件:10 mg组8例(11%),30 mg组4例(5%)。
  • 30 mg组2例(3%)患者在研究期间死亡(肺动脉血栓形成和心肺衰竭),均判定与研究药物无关。

关键数值与推荐

  • 若第4个月时尿游离皮质醇均值>1.5倍正常上限,以及第7、9或12个月时>1.0倍正常上限,可上调剂量(10 mg至30 mg或30 mg至40 mg)。
  • 主要终点为第7个月时尿游离皮质醇均值≤正常上限的患者比例。

临床怎么用

  • 研究者认为长效帕瑞肽是部分经初始手术后持续或复发疾病、或不适合手术的库欣病患者的有效治疗选择,并提供方便的每月给药方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cushing's disease is a rare debilitating endocrine disorder for which few prospective interventional studies have been done. We report results of the first phase 3 trial assessing long-acting intramuscular pasireotide in patients with Cushing's disease. METHODS: In this phase 3 clinical trial we recruited patients aged 18 years or older with persistent, recurrent, or de-novo (non-surgical candidates) Cushing's disease who had a mean urinary free cortisol (mUFC) concentration (from three 24 h samples) of 1·5-5·0 times the upper limit of normal (ULN), a normal or greater than normal morning plasma adrenocorticotropic hormone concentration, and a pituitary source of Cushing's syndrome, from 57 sites across 19 countries. Exclusion criteria included previous pasireotide treatment, mitotane therapy within 6 months, and pituitary irradiation within 10 years. We randomly allocated patients 1:1 (block size of four) using an interactive-response-technology system to intramuscular pasireotide 10 mg or 30 mg every 4 weeks for 12 months (in the core phase). We stratified randomisation by screening mUFC concentration (1·5 to <2·0 × ULN and 2·0-5·0 × ULN). The dose could be uptitrated (from 10 mg to 30 mg or from 30 mg to 40 mg) at month 4 if the mUFC concentration was greater than 1·5 × ULN, and at month 7, month 9, or month 12 if the mUFC concentration was greater than 1·0 × ULN. Investigators, patients, site personnel, and those assessing outcomes were masked to dose group allocation. The primary endpoint was the proportion of patients in each group with an mUFC concentration of less than or equal to the ULN at month 7. Efficacy analyses were based on intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01374906. FINDINGS: Between Dec 28, 2011, and Dec 9, 2014, we randomly allocated 150 patients to receive pasireotide 10 mg (74 [49%] patients) or 30 mg (76 [51%] patients). The primary efficacy endpoint was met by 31 (41·9% [95% CI 30·5-53·9]) of 74 patients in the 10 mg group and 31 (40·8% [29·7-52·7]) of 76 in the 30 mg group. The most common adverse events were hyperglycaemia (36 [49%] in the 10 mg group and 36 [47%] in the 30 mg group), diarrhoea (26 [35%] and 33 [43%]), cholelithiasis (15 [20%] and 34 [45%]), diabetes mellitus (14 [19%] and 18 [24%]), and nausea (15 [20%] and 16 [21%]). Serious adverse events suspected to be study drug related were reported in eight (11%) patients in the 10 mg group and four (5%) in the 30 mg group. Two (3%) patients in the 30 mg group died during the study (pulmonary artery thrombosis and cardiorespiratory failure); neither death was judged to be related to the study drug. INTERPRETATION: Long-acting pasireotide normalised mUFC concentration in about 40% of patients with Cushing's disease at month 7 and had a similar safety profile to that of twice-daily subcutaneous pasireotide. Long-acting pasireotide is an efficacious treatment option for some patients with Cushing's disease who have persistent or recurrent disease after initial surgery or are not surgical candidates, and provides a convenient monthly administration schedule. FUNDING: Novartis Pharma AG.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2017. PMID: 29032078. doi:10.1016/S2213-8587(17)30326-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。